In the ER+/PgR-/HER2- group, the ER percentage ranged from 1% to 100% (median, 71.8%), and the tumours of 22 patients expressed ER at levels <10%, whereas the PgR percentage ranged from 0% to 15% (median, 3.3%). This evidence concerns the gene PGR and neoplasm.